p27 KIP 1 Antibody

About the Target

CDKN1B is a target of interest in many antibody-based workflows. p27 KIP 1 is a cyclin-dependent kinase inhibitor (CDKI) that plays a pivotal role in regulating the cell cycle, particularly during the G1 phase, by inhibiting cyclin-CDK complexes such as cyclin E-CDK2 and cyclin D-CDK4/6. p27 is an intrinsically disordered protein (IDP) with an N-terminal domain that binds cyclin-CDK complexes, a central region mediating protein-protein interactions, and a C-terminal domain subject to post-translational modifications. By binding to these cyclin-CDK complexes, p27 prevents their activation, halting the transition from the G1 to S phase and controlling cell proliferation. p27 is regulated through post-translational modifications, including phosphorylation. Depending on the literature source, CDKN1B may also be discussed as p27 KIP 1 and CDKN1B/Kip1 p27.

Reported cellular context includes cytoplasm, endosome, and nucleus, which can matter when signal is compared across treatments or changing cell states. Following CDKN1B across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

CDKN1B is commonly interpreted in the context of cancer and cell cycle research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm, endosome, and nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cytoplasm, endosome, and nucleus across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• cell-cycle linked differences in abundance, timing, or compartmental enrichment
• co-patterning with orthogonal markers and control conditions that clarify pathway state

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for CDKN1B. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in CDKN1B reflect biology rather than handling. When interpreting CDKN1B, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep CDKN1B trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.